Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma

Yukimoto, Atsushi; Hirooka, Masashi; Hiraoka, Atsushi; Michitaka, Kojiro; Ochi, Hironori; Joko, Kouji; Imai, Yusuke; Watanabe, Takao; Koizumi, Yohei; Yoshida, Osamu; Abe, Masanori; Hiasa, Yoichi

doi:10.1093/jjco/hyy153

Record: found
Abstract: not found
Article: not found

Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma

Author(s): Atsushi Yukimoto ¹ , Masashi Hirooka ¹ , Atsushi Hiraoka ² , Kojiro Michitaka ² , Hironori Ochi ³ , Kouji Joko ³ , Yusuke Imai ¹ , Takao Watanabe ¹ , Yohei Koizumi ¹ , Osamu Yoshida ¹ , Masanori Abe ¹ , Yoichi Hiasa ¹

Publication date Created: October 31 2018

Publication date (Electronic): October 31 2018

Journal: Japanese Journal of Clinical Oncology

Publisher: Oxford University Press (OUP)

Read this article at

ScienceOpenPublisher

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Japanese Journal of Clinical Oncology

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1465-3621

Publication date Created: January 2019

Publication date Created: January 01 2019

Publication date Created: October 31 2018

Publication date Other: January 2019

Publication date (Print): January 01 2019

Publication date (Electronic): October 31 2018

Volume: 49

Issue: 1

Pages: 42-47

Affiliations

[1 ]Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan

[2 ]Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan

[3 ]Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan

Article

DOI: 10.1093/jjco/hyy153

SO-VID: 5b2e66cf-c098-4cb4-8947-cddf27dbbdcc

License:

https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma

Read this article at

Related collections

Genome Engineering using CRISPR

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 3,343

Cited by 20